{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:55:18Z","timestamp":1793732118930,"version":"4.6.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005301","name":"American College of Surgeons","doi-asserted-by":"publisher","award":["Resident Research Scholarship"],"award-info":[{"award-number":["Resident Research Scholarship"]}],"id":[{"id":"10.13039\/100005301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015127","name":"Commonwealth Foundation for Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015127","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32CA126607"],"award-info":[{"award-number":["5T32CA126607"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA153952"],"award-info":[{"award-number":["T32CA153952"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA268083"],"award-info":[{"award-number":["U54CA268083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Black in Cancer\/Emerald Foundation"},{"name":"Johns Hopkins SPORE in Gastrointestinal Cancer"},{"name":"Giovanis Institute for Translational Cell Biology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1245\/s10434-023-14696-6","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T16:01:32Z","timestamp":1704384092000},"page":"1996-2007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intra- and Interpatient Drug Response Heterogeneity Exist in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Nongynecologic Cancers"],"prefix":"10.1245","volume":"31","author":[{"given":"Shannon N.","family":"Radomski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Dunworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junior J.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan B.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Ewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"9","key":"14696_CR1","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ejso.2022.05.030","volume":"48","author":"S Frassini","year":"2022","unstructured":"Frassini S, Calabretto F, Granieri S, et al. Intraperitoneal chemotherapy in the management of pancreatic adenocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2022;48(9):1911\u201321. https:\/\/doi.org\/10.1016\/j.ejso.2022.05.030.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"14696_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jss.2018.06.012","volume":"232","author":"MS Hughes","year":"2018","unstructured":"Hughes MS, Lo WM, Beresnev T, et al. A phase II trial of cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent adrenocortical carcinoma. J Surg Res. 2018;232:383\u20138. https:\/\/doi.org\/10.1016\/j.jss.2018.06.012.","journal-title":"J Surg Res"},{"issue":"3","key":"14696_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jso.23633","volume":"110","author":"U Rudloff","year":"2014","unstructured":"Rudloff U, Langan RC, Mullinax JE, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110(3):275\u201384. https:\/\/doi.org\/10.1002\/jso.23633.","journal-title":"J Surg Oncol"},{"issue":"2","key":"14696_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol"},{"issue":"3","key":"14696_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Van Driel","year":"2018","unstructured":"Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"N Engl J Med."},{"issue":"1","key":"14696_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1245\/s10434-011-1840-y","volume":"19","author":"H El Halabi","year":"2012","unstructured":"El Halabi H, Gushchin V, Francis J, et al. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS\/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. Ann Surg Oncol. 2012;19(1):110\u20134. https:\/\/doi.org\/10.1245\/s10434-011-1840-y.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"14696_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/02656736.2017.1320591","volume":"33","author":"KK Turaga","year":"2017","unstructured":"Turaga KK, Deraco M, Alexander HR. Current management strategies for peritoneal mesothelioma. Int J Hyperthermia. 2017;33(5):579\u201381. https:\/\/doi.org\/10.1080\/02656736.2017.1320591.","journal-title":"Int J Hyperthermia"},{"key":"14696_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.suronc.2019.03.004","volume":"29","author":"L Benhaim","year":"2019","unstructured":"Benhaim L, Faron M, Gelli M, et al. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei. Surg Oncol. 2019;29:78\u201383. https:\/\/doi.org\/10.1016\/j.suronc.2019.03.004.","journal-title":"Surg Oncol"},{"key":"14696_CR9","doi-asserted-by":"publisher","first-page":"650098","DOI":"10.3389\/fonc.2021.650098","volume":"11","author":"O Kranenburg","year":"2021","unstructured":"Kranenburg O, van der Speeten K, de Hingh I. Peritoneal metastases from colorectal cancer: defining and addressing the challenges. Front Oncol. 2021;11:650098. https:\/\/doi.org\/10.3389\/fonc.2021.650098.","journal-title":"Front Oncol"},{"issue":"1","key":"14696_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12957-016-1042-y","volume":"14","author":"D Liu","year":"2016","unstructured":"Liu D, Lu M, Li J, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14(1):305. https:\/\/doi.org\/10.1186\/s12957-016-1042-y.","journal-title":"World J Surg Oncol."},{"key":"14696_CR11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10193-w","author":"A Bhatt","year":"2021","unstructured":"Bhatt A, de Hingh I, Van Der Speeten K, et al. HIPEC methodology and regimens: The need for an expert consensus. Ann Surg Oncol. 2021. https:\/\/doi.org\/10.1245\/s10434-021-10193-w.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"14696_CR12","doi-asserted-by":"publisher","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","volume":"156","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363. https:\/\/doi.org\/10.1001\/jamasurg.2020.6363.","journal-title":"JAMA Surg"},{"issue":"7","key":"14696_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/jso.23728","volume":"110","author":"A Prada-Villaverde","year":"2014","unstructured":"Prada-Villaverde A, Esquivel J, Lowy AM, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110(7):779\u201385. https:\/\/doi.org\/10.1002\/jso.23728.","journal-title":"J Surg Oncol"},{"issue":"6","key":"14696_CR14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/jso.23228","volume":"107","author":"G Glockzin","year":"2013","unstructured":"Glockzin G, von Breitenbuch P, Schlitt HJ, Piso P. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis. J Surg Oncol. 2013;107(6):574\u20138. https:\/\/doi.org\/10.1002\/jso.23228.","journal-title":"J Surg Oncol"},{"issue":"6","key":"14696_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jso.23546","volume":"109","author":"D Hompes","year":"2014","unstructured":"Hompes D, D\u2019Hoore A, Wolthuis A, et al. The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol. 2014;109(6):527\u201332. https:\/\/doi.org\/10.1002\/jso.23546.","journal-title":"J Surg Oncol"},{"issue":"2","key":"14696_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejso.2017.10.216","volume":"44","author":"WJ van Eden","year":"2018","unstructured":"van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2018;44(2):220\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2017.10.216.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"1","key":"14696_CR17","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.jss.2012.01.015","volume":"179","author":"K Votanopoulos","year":"2013","unstructured":"Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res. 2013;179(1):e133\u20139. https:\/\/doi.org\/10.1016\/j.jss.2012.01.015.","journal-title":"J Surg Res"},{"issue":"4","key":"14696_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2017.12.027","volume":"226","author":"EA Levine","year":"2018","unstructured":"Levine EA, Votanopoulos KI, Shen P, et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg. 2018;226(4):434\u201343. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2017.12.027.","journal-title":"J Am Coll Surg"},{"issue":"3","key":"14696_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1245\/s10434-019-08064-6","volume":"27","author":"O Moaven","year":"2020","unstructured":"Moaven O, Votanopoulos KI, Shen P, et al. Health-related quality of life after cytoreductive surgery\/HIPEC for mucinous appendiceal cancer: results of a multicenter randomized trial comparing oxaliplatin and mitomycin. Ann Surg Oncol. 2020;27(3):772\u201380. https:\/\/doi.org\/10.1245\/s10434-019-08064-6.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"14696_CR20","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.ejso.2019.07.017","volume":"45","author":"TH Brunsell","year":"2019","unstructured":"Brunsell TH, Cengija V, Sveen A, et al. Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. Eur J Surg Oncol. 2019;45(12):2340\u20136. https:\/\/doi.org\/10.1016\/j.ejso.2019.07.017.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"14696_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ccell.2018.06.004","volume":"34","author":"G Siravegna","year":"2018","unstructured":"Siravegna G, Lazzari L, Crisafulli G, et al. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell. 2018;34(1):148-62.e7. https:\/\/doi.org\/10.1016\/j.ccell.2018.06.004.","journal-title":"Cancer Cell"},{"issue":"11","key":"14696_CR22","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1016\/j.ejca.2013.03.027","volume":"49","author":"CS van Kessel","year":"2013","unstructured":"van Kessel CS, Samim M, Koopman M, et al. Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases. Eur J Cancer. 2013;49(11):2486\u201393. https:\/\/doi.org\/10.1016\/j.ejca.2013.03.027.","journal-title":"Eur J Cancer"},{"issue":"15","key":"14696_CR23","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-19-3637","volume":"26","author":"J Bruun","year":"2020","unstructured":"Bruun J, Kryeziu K, Eide PW, et al. Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. Clin Cancer Res. 2020;26(15):4107\u201319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3637.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"14696_CR24","doi-asserted-by":"publisher","first-page":"107762","DOI":"10.1016\/j.celrep.2020.107762","volume":"31","author":"CJ de Witte","year":"2020","unstructured":"de Witte CJ, Espejo Valle-Inclan J, Hami N, et al. Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses. Cell Rep. 2020;31(11):107762. https:\/\/doi.org\/10.1016\/j.celrep.2020.107762.","journal-title":"Cell Rep"},{"issue":"2","key":"14696_CR25","doi-asserted-by":"publisher","first-page":"e121490","DOI":"10.1172\/jci.insight.121490","volume":"4","author":"L Li","year":"2019","unstructured":"Li L, Knutsdottir H, Hui K, et al. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight. 2019;4(2):e121490. https:\/\/doi.org\/10.1172\/jci.insight.121490.","journal-title":"JCI Insight"},{"issue":"4","key":"14696_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/path.5684","volume":"254","author":"LD Wood","year":"2021","unstructured":"Wood LD, Ewald AJ. Organoids in cancer research: a review for pathologist-scientists. J Pathol. 2021;254(4):395\u2013404. https:\/\/doi.org\/10.1002\/path.5684.","journal-title":"J Pathol"},{"issue":"1","key":"14696_CR27","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s41467-021-21300-6","volume":"12","author":"S Karkampouna","year":"2021","unstructured":"Karkampouna S, La Manna F, Benjak A, et al. Patient-derived xenografts and organoids model therapy response in prostate cancer. Nat Commun. 2021;12(1):1117. https:\/\/doi.org\/10.1038\/s41467-021-21300-6.","journal-title":"Nat Commun"},{"issue":"513","key":"14696_CR28","doi-asserted-by":"publisher","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","volume":"11","author":"SN Ooft","year":"2019","unstructured":"Ooft SN, Weeber F, Dijkstra KK, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med. 2019;11(513):eaay2574. https:\/\/doi.org\/10.1126\/scitranslmed.aay2574.","journal-title":"Sci Transl Med"},{"key":"14696_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.gde.2019.02.003","volume":"54","author":"H Tiriac","year":"2019","unstructured":"Tiriac H, Plenker D, Baker LA, Tuveson DA. Organoid models for translational pancreatic cancer research. Curr Opin Genet Dev. 2019;54:7\u201311. https:\/\/doi.org\/10.1016\/j.gde.2019.02.003.","journal-title":"Curr Opin Genet Dev"},{"key":"14696_CR30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.semcancer.2018.06.005","volume":"53","author":"PW Nagle","year":"2018","unstructured":"Nagle PW, Plukker JTM, Muijs CT, van Luijk P, Coppes RP. Patient-derived tumor organoids for prediction of cancer treatment response. Semin Cancer Biol. 2018;53:258\u201364. https:\/\/doi.org\/10.1016\/j.semcancer.2018.06.005.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"14696_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1245\/s10434-018-7008-2","volume":"26","author":"KI Votanopoulos","year":"2019","unstructured":"Votanopoulos KI, Mazzocchi A, Sivakumar H, et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. Ann Surg Oncol. 2019;26(1):139\u201347. https:\/\/doi.org\/10.1245\/s10434-018-7008-2.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"14696_CR32","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/s41596-020-0335-3","volume":"15","author":"V Padmanaban","year":"2020","unstructured":"Padmanaban V, Grasset EM, Neumann NM, et al. Organotypic culture assays for murine and human primary and metastatic-site tumors. Nat Protoc. 2020;15(8):2413\u201342. https:\/\/doi.org\/10.1038\/s41596-020-0335-3.","journal-title":"Nat Protoc"},{"issue":"1","key":"14696_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8(1):1\u201324. https:\/\/doi.org\/10.1038\/s41392-023-01419-2.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"14696_CR34","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","volume":"141","author":"T Sato","year":"2011","unstructured":"Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett\u2019s epithelium. Gastroenterology. 2011;141(5):1762\u201372. https:\/\/doi.org\/10.1053\/j.gastro.2011.07.050.","journal-title":"Gastroenterology"},{"issue":"6","key":"14696_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1530\/EJE-20-1423","volume":"184","author":"LS Landwehr","year":"2021","unstructured":"Landwehr LS, Schreiner J, Appenzeller S, et al. A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden. Eur J Endocrinol. 2021;184(6):823\u201335. https:\/\/doi.org\/10.1530\/EJE-20-1423.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"14696_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1530\/ERC-17-0447","volume":"25","author":"K Kiseljak-Vassiliades","year":"2018","unstructured":"Kiseljak-Vassiliades K, Zhang Y, Bagby SM, et al. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer. 2018;25(4):437\u201351. https:\/\/doi.org\/10.1530\/ERC-17-0447.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"14696_CR37","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5.","journal-title":"Sci Rep"},{"key":"14696_CR38","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.5114\/pjr.2023.125027","volume":"88","author":"MA Szadkowska","year":"2023","unstructured":"Szadkowska MA, Pa\u0142ucki J, Cieszanowski A. Diagnosis and treatment of peritoneal carcinomatosis\u2014a comprehensive overview. Pol J Radiol. 2023;88:e89-97. https:\/\/doi.org\/10.5114\/pjr.2023.125027.","journal-title":"Pol J Radiol"},{"issue":"3","key":"14696_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.crad.2012.07.015","volume":"68","author":"S Burbidge","year":"2013","unstructured":"Burbidge S, Mahady K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clin Radiol. 2013;68(3):251\u20135. https:\/\/doi.org\/10.1016\/j.crad.2012.07.015.","journal-title":"Clin Radiol"},{"issue":"10","key":"14696_CR40","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/bjs.11206","volume":"106","author":"I Ubink","year":"2019","unstructured":"Ubink I, Bolhaqueiro ACF, Elias SG, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg. 2019;106(10):1404\u201314. https:\/\/doi.org\/10.1002\/bjs.11206.","journal-title":"Br J Surg"},{"issue":"13","key":"14696_CR41","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1245\/s10434-020-08790-2","volume":"27","author":"SD Forsythe","year":"2020","unstructured":"Forsythe SD, Sasikumar S, Moaven O, et al. Personalized identification of optimal HIPEC perfusion protocol in patient-derived tumor organoid platform. Ann Surg Oncol. 2020;27(13):4950\u201360. https:\/\/doi.org\/10.1245\/s10434-020-08790-2.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"14696_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijpharm.2017.07.084","volume":"531","author":"P Roy","year":"2017","unstructured":"Roy P, Canet-Jourdan C, Annereau M, et al. Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC. Int J Pharm. 2017;531(1):143\u201352. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.07.084.","journal-title":"Int J Pharm"},{"key":"14696_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-022-00891-3","author":"RA Erali","year":"2022","unstructured":"Erali RA, Forsythe SD, Gironda DJ, et al. Utilizing patient-derived organoids in the management of colorectal cancer with peritoneal metastases: a review of current literature. J Gastrointest Cancer. 2022. https:\/\/doi.org\/10.1007\/s12029-022-00891-3.","journal-title":"J Gastrointest Cancer"},{"issue":"1","key":"14696_CR44","doi-asserted-by":"publisher","first-page":"11640","DOI":"10.1038\/s41598-023-38545-4","volume":"13","author":"SD Forsythe","year":"2023","unstructured":"Forsythe SD, Erali RA, Edenhoffer N, et al. Cisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform. Sci Rep. 2023;13(1):11640. https:\/\/doi.org\/10.1038\/s41598-023-38545-4.","journal-title":"Sci Rep"},{"issue":"4","key":"14696_CR45","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1158\/1078-0432.CCR-20-4116","volume":"28","author":"JE Grossman","year":"2022","unstructured":"Grossman JE, Muthuswamy L, Huang L, et al. Organoid sensitivity correlates with therapeutic response in patients with pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(4):708\u201318. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4116.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"14696_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","volume":"26","author":"Y Yao","year":"2020","unstructured":"Yao Y, Xu X, Yang L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell. 2020;26(1):17-26.e6. https:\/\/doi.org\/10.1016\/j.stem.2019.10.010.","journal-title":"Cell Stem Cell"},{"issue":"6378","key":"14696_CR47","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920\u20136. https:\/\/doi.org\/10.1126\/science.aao2774.","journal-title":"Science"},{"issue":"11","key":"14696_CR48","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","volume":"8","author":"SJ Hill","year":"2018","unstructured":"Hill SJ, Decker B, Roberts EA, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018;8(11):1404\u201321. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0474.","journal-title":"Cancer Discov"},{"issue":"1\u20132","key":"14696_CR49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1\u20132):373-86.e10. https:\/\/doi.org\/10.1016\/j.cell.2017.11.010.","journal-title":"Cell"},{"issue":"Suppl 1","key":"14696_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1245\/s10434-023-13332-7","volume":"30","author":"RA Erali","year":"2023","unstructured":"Erali RA, Forsythe S, Gironda D, Wajih N, Mangieri CW, Shen P, Levine E, Soker S, Votanopoulous K. Utilizing organoids to study perfusate selection in appendiceal cancer patient undergoing repeat HIPEC. Society of Surgical Oncology SSO 2023 \u2013 International Conference on Surgical Cancer Care. Ann Surg Oncol. 2023;30(Suppl 1):1\u2013257. https:\/\/doi.org\/10.1245\/s10434-023-13332-7.","journal-title":"Ann Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14696-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14696-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14696-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T19:15:17Z","timestamp":1706987717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14696-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["14696"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14696-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors received support from the NIH \/ NCI 5T32CA126607 (SNR), NIH\/NCI T32CA153952 (MD), NIH\/NCI U54CA268083 (AJE), American College of Surgeons Resident Research Scholarship (SNR), the Commonwealth Foundation for Cancer Research (FMJ, AJE), the Johns Hopkins SPORE in Gastrointestinal Cancer at the Sidney Kimmel Comprehensive Cancer Center (SNR, AJE), the Giovanis Institute for Translational Cell Biology (AJE), and the Black in Cancer\/Emerald Foundation Postdoctoral Fellowship (JJW). AJE has unlicensed patents related to keratin 14 as a prognostic marker and to antibody strategies for anti-cancer therapeutics. AJE is a consultant for BioNTech. AJE\u2019s spouse is an employee of ImmunoCore.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}